BioRegion solutions to manage, treat and control diabetes
<p>To commemorate <strong>World Diabetes Day</strong>, which is celebrated every November 14, we include in this infographic the solutions developed in the BioRegion for the management, treatment and control of diabetes. A market that has raised <strong>3.7 million euros in Catalonia since 2017</strong>.</p>
Diabetes is one of the most common diseases worldwide and one of the main causes of early death in adults, according to the World Health Organization (WHO). In 2010, the total was 285 million people but that figure rose to 463 million by 2019 and the future isn’t heartening: the number of cases is expected to hit 522 million by 2030.
Plus, early diagnosis of this disease is key to preventing all sorts of related complications -kidney failure, myocardial infarction, stroke and amputation of the lower limbs- and even to saving the patient’s life. Furthermore, once a patient has been diagnosed, they have to closely monitor the progression and evolution of the disease at all times.
In this sense, new technology has promoted better adherence to treatment, more effective monitoring and follow-up of patients, and better quality of life, among other benefits. And, at the same time, digitalization had helped healthcare professionals continue learning new knowledge and skills to further improve care for these patients.
To mark World Diabetes Day on December 14, we’ve put together this infographic on the solutions developed in the BioRegion to manage, treat and control diabetes. A market that has raised €3.7 million in Catalonia since 2017.
Although it isn’t on the infographic, Roche opened its Roche Diabetes Care Health & Digital Solutions headquarters in Catalonia in 2015 to tackle challenges that diabetes and conditions associated with this disease pose for the future of patients, the healthcare system and society in general.
Innovative projects in diabetes: VHIR and IDIBAPS
In terms of research centers, one of the most active in diabetes and metabolism research in the BioRegion is the Vall d'Hebron Research Institute (VHIR), which in recent years has developed outstanding projects such as DDP4, a topical eye treatment for the retinal neurodegeneration caused by diabetes; Hemopexin, a new approach for the treatment of Diabetic Macular Edema (DME); and SOCS1, a peptide (set of molecules bound together) for the treatment of chronic complications of diabetes. The August Pi i Sunyer Biomedical Research Institute (IDIBAPS) is also a reference center on this pathology. They're currently developing 10 active research projects focused on diabetes and its prevention.
